Im Ellie Eunkyung sold $22K of CBIO
Im Ellie Eunkyung (Chief Medical Officer) sold 1,219 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.99 on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the CMO’s open-market sale (1,219 shares) at a stated price, with holdings after the transaction and confirmation of a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for insider-selling patterns, but this specific disclosure is likely low-signal due to the 10b5-1 framing.
What to watch
Check whether subsequent Form 4s show repeated large sales outside the plan, changes in total holdings, or concurrent insider buys that could offset the signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Crescent Biopharma, Inc. (CBIO).
Ticker impact
Crescent Biopharma CMO Im Ellie Eunkyung sold 1,219 shares at $17.99 via a 10b5-1 plan, disclosed in a fresh Form 4.
Low near-term impact; any reaction is likely muted unless follow-on filings show unusual acceleration or size.
The filing is a primary SEC Form 4 and includes exact trade size/price, but it is explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight.
Market effects
Minimal; this is company-specific insider activity with no sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than negative fundamentals; traders may ignore it unless there’s a pattern of outsized sales.
Key entities
- issuerCrescent Biopharma, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderIm Ellie Eunkyung
Chief Medical Officer who executed the reported sale.
- trading mechanism10b5-1 plan
Pre-arranged plan cited as the basis for the sale.
